NCT03349073

An Extension Study for T-1101 (Tosylate) to Treat Advanced Refractory Solid Tumors

An Extension Study of T-1101 (Tosylate) Administered Orally to Patients With Advanced Refractory Solid Tumors

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 3 (actual)
• Sponsor: Taivex Therapeutics Corporation · Industry
• Sex: All
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

T-1101 is a novel anti-cancer agent being developed by Taivex Therapeutics Corporation, and is being studied in a phase I dose escalation trial, protocol TAI-001. That trial's primary aim is to study the safety and tolerability of T-1101 (Tosylate) in subjects with advanced refractory solid tumors, and provides for a maximum of 2 cycles of treatment. At the end of 2 cycles of treatment, it is likely that some patients will be continuing to receive clinical benefit from T-1101 (Tosylate). The intention of this program is to enable these patients to continue to receive T-1101 (Tosylate) at the discretion of the principal investigators and Taivex Therapeutics Corporation.

Conditions

• Advanced Refractory Solid Tumors

Interventions

Type	Name	Description
DRUG	T-1101 (Tosylate)	T-1101 (Tosylate) powder in bottle

Timeline

• Start date: 2017-09-14
• Primary completion: 2019-06-24
• Completion: 2019-06-24
• First posted: 2017-11-21
• Last updated: 2022-11-18

Locations

4 sites across 1 country: Taiwan